IP Library Granted Patent US 9,902,940
Granted Patent B2
US 9,902,940 · App. 13/155,435 · Granted Feb 27, 2018

Human blood-brain barrier endothelial cells derived from pluripotent stem cells and blood-brain barrier model thereof

Inventors: Eric V. Shusta (Madison, WI); Samira Azarin (Madison, WI); Sean Palecek (Verona, WI); Ethan Lippmann (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation
C12N5/069C12N5/0697C12N2502/086C12N2502/28C12N2506/45C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,902,940
App. No.
13/155,435
Granted
Feb 27, 2018
Kind
B2
Abstract

A model blood brain barrier obtained from hPSCs is disclosed.

Claims (16)

1. A method of producing a blood brain barrier model from endothelial cells, comprising the steps of:

(a) growing human pluripotent stem cells (hPSCs), wherein all the hPSCs are grown adherently on an extracellular matrix;

(b) inducing differentiation of the hPSCs by culturing the hPSCs in unconditioned medium on the extracellular matrix for a sufficient amount of time until the endothelial cells form from the hPSCs and endothelial cell (EC) regions are observed, wherein no fibroblast growth factor (FGF) is present in the unconditioned medium, and

(c) expanding the EC regions by culturing the endothelial cells in EC medium, wherein the expanded endothelial cells are glucose transporter+(GLUT-1+), platelet endothelial cell adhesion molecule+(PECAM-1+), claudin-5+, occludin+, zonula occludens-1+(ZO-1+) and p-glycoprotein+, wherein the EC regions are purified after step (b), and

the method additionally comprising the step of growing the endothelial cells of step (c) to confluent monolayers of the endothelial cells, wherein the blood brain barrier model is obtained, wherein the blood brain barrier model is evinced by expression of various blood-brain barrier transporters.

2. The method of claim 1 additionally comprising the step of co-culturing the expanded cells of step (c) with a cell-type selected from the group consisting of astrocytes, neurons, neural progenitor cells, and pericytes.

3. The method of claim 2 wherein the co-culturing is with at least two cell types from the group.

4. A method of producing a blood brain barrier model from endothelial cells, comprising the steps of:

(a) growing human pluripotent stem cells (hPSCs), wherein all the hPSCs are grown adherently on an extracellular matrix;

(b) inducing differentiation of the hPSCs by culturing the hPSCs in unconditioned medium on the extracellular matrix for a sufficient amount of time until the endothelial cells form from the hPSCs and endothelial cell (EC) regions are observed, wherein no fibroblast growth factor (FGF) is present in the unconditioned medium, and

(c) expanding the EC regions by culturing the endothelial cells in EC medium, wherein the expanded endothelial cells are glucose transporter+(GLUT-1+), platelet endothelial cell adhesion molecule+(PECAM-1+), claudin-5+, occludin+, zonula occludens-1+(ZO-1+) and p-glycoprotein+,

the method additionally comprising the step of growing the endothelial cells of step (c) to confluent monolayers of the endothelial cells, wherein the blood brain barrier model is obtained, wherein the blood brain barrier model is evinced by expression of various blood-brain barrier transporters.

5. The method of claim 4 , wherein the hPSCs are selected from the group consisting of human embryonic stem cells and induced pluripotent stem cells.

6. The method of claim 4 , wherein the hPSCs are derived from a human patient.

7. The method of claim 4 wherein the expanded cells of step (c) are grown on a surface comprising extracellular matrix proteins, and wherein the expanded cells are von Willebrand factor+ and vascular endothelial (VE)-cadherin+.

8. The method of claim 4 , wherein the method further comprises the step of taking a trans-endothelial electrical resistance (TEER) measurement of the blood brain barrier model, wherein the TEER measurement is ≧800 Ω×cm 2 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2011
From: SHUSTA, ERIC; AZARIN, SAMIRA; PALECEK, SEAN; LIPPMANN, ETHAN
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 026960/0973 →
CONFIRMATORY LICENSE Recorded Jun 17, 2011
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026465/0103 →
Continuity (2)
Provisional Application 61355901 · Jun 17, 2010
Related Publication 20120015395A1 · Jan 19, 2012